scholarly journals Which set of embryo variables is most predictive for live birth? A prospective study in 6252 single embryo transfers to construct an embryo score for the ranking and selection of embryos

2014 ◽  
Vol 30 (1) ◽  
pp. 28-36 ◽  
Author(s):  
A. Rhenman ◽  
L. Berglund ◽  
T. Brodin ◽  
M. Olovsson ◽  
K. Milton ◽  
...  
Keyword(s):  
Prospective Study ◽  
Live Birth ◽  
Ranking And Selection ◽  
Embryo Score ◽  
A Prospective Study ◽  
Selection Of

Working Women's Selection of Care for Their Infants: A Prospective Study*

2000 ◽  
Vol 49 (3) ◽  
pp. 245-255 ◽  
Author(s):  
Elizabeth Puhn Pungello ◽  
Beth Kurtz-Costes
Keyword(s):  
Prospective Study ◽  
A Prospective Study ◽  
Selection Of

ERCC1, class III β-tubulin, p53, and RRM1-tailored selection of personalized chemotherapy for stage IV NSCLC patients: A prospective study.

2012 ◽  
Vol 30 (15_suppl) ◽  
pp. e18087-e18087
Author(s):  
Huiqin Guo ◽  
Yu Zhao ◽  
Jiangyang Lu ◽  
Zejian Li
Keyword(s):  
Prospective Study ◽  
Stage Iv ◽  
Expression Level ◽  
Class Iii ◽  
High Class ◽  
A Prospective Study ◽  
Personalized Chemotherapy ◽  
Selection Of ◽  
Β Tubulin

e18087 Background: ERCC1, class III β-tubulin, p53, and RRM1 are predictive molecular biomarkers of platinum agents, taxel, vinorelbine and gemcitabine respectively in personalized therapies of NSCLC. Tailored therapy with several of these markers suggested patient benefit was reported previously. But there was no report about prospective study involving all of these biomarkers. Here we report a prospective study that patients were treated with the personalized therapy tailored by these 4 markers to assess this new therapy approach. Methods: From Feb. 2009 to Feb. 2011, in our single group at the thoracic surgical department of PUMC hospital, we identified 48 patients with previously untreated stage IV NSCLC, ECOG PS of 0-2, and at least 2 of the 4 low expression level markers were eligible. The expression level of ERCC1, class III β-tubulin, p53, and RRM1 was assayed by immunohistochemical (IHC) staining with the tissue samples obtained from bronchoscopy biopsy, percutaneous lung biopsy or operation. Patients with low ERCC1/low class III β-tubulin expression received cisplatin/taxel, patients with high ERCC1/low class III β-tubulin expression received gemcitabine(with low RRM1 level) or vinorelbine (with low p53 level)/taxel, patients with low ERCC1/high class III β-tubulin expression received cisplatin/gemcitabine(low RRM1) or vinorelbine (low p53), and patients with high ERCC1/high class IIIβ-tubulin expression received gemcitabine/vinorelbine. A follow-up CT was performed after every 2 cycles chemotherapy and every 3 months after chemotherapy. PFS and OS were estimated by the Kaplan-Meier method. Results: Follow-up period was 35 months till Jan. 2012. 16(33.3%) patients died within follow-up period, 32(66.7%) patients are still alive. The overall response(CR+PR) rate is 85.4% with 10CR, 31 PR, 5 SD and 2 PD. Median PFS is 14 months and median OS was 27 months. And 1-year OS was 88.3% Conclusions: Our study suggest ERCC1, class III β-tubulin, p53, and RRM1-tailored selection of personalized chemotherapy of NSCLC could dramatically raise response rate and improve survival over standard chemotherapy. It might be a promising treatment option in the future..

Sign in / Sign up

Export Citation Format

Share Document